How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells

被引：6

作者：

Nagler, Arnon ^{[1
]}

Perriello, Vincenzo Maria ^{[1
,2
,3
,4
]}

Falini, Lorenza ^{[1
,2
,3
,4
]}

Falini, Brunangelo ^{[1
,2
,3
,4
,5
,6
]}

机构：

[1] Sheba Med Ctr, Div Hematol, Tel Hashomer, Israel

[2] Univ Perugia, Inst Hematol, Perugia, Italy

[3] Univ Perugia, Ctr Hematooncol Res, Perugia, Italy

[4] Santa Maria della Misericordia Hosp, Perugia, Italy

[5] Univ Perugia, Sect Hematol, Perugia, Italy

[6] Univ Perugia, Ctr Hematooncol Res CREO, Dept Med, Perugia, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷 / 03期

关键词：

Chimeric antigen receptor (CAR) T cells; CD19; cytokine release syndrome (CRS); immune effector cell-associated neurotoxicity syndrome (ICANS); immunohistochemistry; lymphoma; monoclonal antibodies; TERM-FOLLOW-UP; AXICABTAGENE CILOLEUCEL; ALLOGENEIC TRANSPLANTATION; INFECTIOUS COMPLICATIONS; POLATUZUMAB VEDOTIN; DLBCL PATIENTS; LUNG-CANCER; SINGLE-ARM; FDG PET/CT; THERAPY;

D O I：

10.1111/bjh.18724

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chimeric antigen receptor (CAR) T cells targeting CD19 represent a promising salvage immunotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), offering similar to 40% of long-term responses. In everyday clinical practice, haematologists involved in CAR T cell treatment of patients with R/R DLBCL have to deal with diagnostically complex cases and difficult therapeutic choices. The availability of novel immunotherapeutic agents for R/R DLBCL and recent advances in understanding CAR T-cell failure mechanisms demand a rational approach to identify the best choice for bridging therapy and managing post-CAR T-cell therapy relapses. Moreover, positron emission tomography/computerised tomography may result in false-positive interpretation, highlighting the importance of post-treatment biopsy. In this review, we discuss all above issues, presenting four instructive cases, with the aim to provide criteria and new perspectives for CAR T-cell treatment of DLBCL.

引用

页码：396 / 410

页数：15

共 135 条

[1] Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy [J].

Ababneh, Hazim S. ;

Abramson, Jeremy S. ;

Johnson, P. Connor ;

Patel, Chirayu G. .

RADIOTHERAPY AND ONCOLOGY, 2022, 175 :65-72

[2] Post-CAR relapse in DLBCL: a fork in the road Comment [J].

Abramson, Jeremy S. .

BLOOD, 2022, 140 (24) :2527-2529

[3] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[4] CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights [J].

Ali, Alaa ;

Goy, Andre ;

Dunleavy, Kieron .

BLOOD, 2022, 140 (13) :1461-1469

[5] Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy [J].

不详 .

BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (01) :45-51

[6] Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19 [J].

Asnani, Mukta ;

Hayer, Katharina E. ;

Naqvi, Ammar S. ;

Zheng, Sisi ;

Yang, Scarlett Y. ;

Oldridge, Derek ;

Ibrahim, Fadia ;

Maragkakis, Manolis ;

Gazzara, Matthew R. ;

Black, Kathryn L. ;

Bagashev, Asen ;

Taylor, Deanne ;

Mourelatos, Zissimos ;

Grupp, Stephan A. ;

Barrett, David ;

Maris, John M. ;

Sotillo, Elena ;

Barash, Yoseph ;

Thomas-Tikhonenko, Andrei .

LEUKEMIA, 2020, 34 (04) :1202-1207

[7] Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? [J].

Bacher, Ulrike ;

Klyuchnikov, Evgeny ;

Le-Rademacher, Jennifer ;

Carreras, Jeanette ;

Armand, Philippe ;

Bishop, Michael R. ;

Bredeson, Christopher N. ;

Cairo, Mitchell S. ;

Fenske, Timothy S. ;

Freytes, Cesar O. ;

Gale, Robert Peter ;

Gibson, John ;

Isola, Luis M. ;

Inwards, David J. ;

Laport, Ginna G. ;

Lazarus, Hillard M. ;

Maziarz, Richard T. ;

Wiernik, Peter H. ;

Schouten, Harry C. ;

Slavin, Shimon ;

Smith, Sonali M. ;

Vose, Julie M. ;

Waller, Edmund K. ;

Hari, Parameswaran N. .

BLOOD, 2012, 120 (20) :4256-4262

[8] Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma [J].

Baird, John H. ;

Epstein, David J. ;

Tamaresis, John S. ;

Ehlinger, Zachary ;

Spiegel, Jay Y. ;

Craig, Juliana ;

Claire, Gursharan K. ;

Frank, Matthew J. ;

Muffly, Lori ;

Shiraz, Parveen ;

Meyer, Everett ;

Arai, Sally ;

Brown, Janice ;

Johnston, Laura ;

Lowsky, Robert ;

Negrin, Robert S. ;

Rezvani, Andrew R. ;

Weng, Wen-Kai ;

Latchford, Theresa ;

Sahaf, Bita ;

Mackall, Crystal L. ;

Miklos, David B. ;

Sidana, Surbhi .

BLOOD ADVANCES, 2021, 5 (01) :143-155

[9] Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy [J].

Bannerji, Rajat ;

Allan, John N. ;

Arnason, Jon E. ;

Brown, Jennifer R. ;

Advani, Ranjana ;

Ansell, Stephen M. ;

O'Brien, Susan M. ;

Duell, Johannes ;

Martin, Peter ;

Joyce, Robin M. ;

Li, Jingjin ;

Flink, Dina M. ;

Zhu, Min ;

Weinreich, David M. ;

Yancopoulos, George D. ;

Sirulnik, Andres ;

Chaudhry, Aafia ;

Ambati, Srikanth R. ;

Topp, Max S. .

BLOOD, 2020, 136

[10] GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany [J].

Bethge, Wolfgang A. ;

Martus, Peter ;

Schmitt, Michael ;

Holtick, Udo ;

Subklewe, Marion ;

von Tresckow, Bastian ;

Ayuk, Francis ;

Wagner-Drouet, Eva Marie ;

Wulf, Gerald G. ;

Marks, Reinhard ;

Penack, Olaf ;

Schnetzke, Ulf ;

Koenecke, Christian ;

von Bonin, Malte ;

Stelljes, Matthias ;

Glass, Bertram ;

Baldus, Claudia D. ;

Vucinic, Vladan ;

Mougiakakos, Dimitrios ;

Topp, Max ;

Fante, Matthias A. ;

Schroers, Roland ;

Bayir, Lale ;

Borchmann, Peter ;

Buecklein, Veit ;

Hasenkamp, Justin ;

Hanoun, Christine ;

Thomas, Simone ;

Beelen, Dietrich W. ;

Lengerke, Claudia ;

Kroeger, Nicolaus ;

Dreger, Peter .

BLOOD, 2022, 140 (04) :349-358

← 1 2 3 4 5 6 7 8 9 10 →